◈ Nootpedia
Compact view
Research pass: medium Compound NOT-RELEVANT HIGH

Duloxetine

Extended Research
◈ Extended Research ◈

Our depth — beyond the mirror

Deeper analysis, verdict reasoning, and per-archetype recommendations from our research team.

▸ Our verdict NOT-RELEVANT HIGH

No indication for Dylan. Better-tolerated than venlafaxine but similar emotional/sexual side effects. Pain dual-indication (DPN, fibromyalgia, chronic LBP) is unique value but Dylan has no pain syndrome.

Research pass: medium
▸ Decision matrix by user profile Per-archetype
  • Dylan20-30, brain-priority, high cognitive workload (Dylan-archetype)
    NOT-RELEVANT
  • 30-50, executive maintenance
    NOT-RELEVANT

    unless mood + pain comorbidity.

  • 50+, mild cognitive decline
    NOT-RELEVANT

    for cognition.

  • Anxiety-prone
    OPTIONAL-ADD

    if SSRI fails or if comorbid pain.

  • High athletic load, tested status
    SKIP-FOR-NOW

    Same drive/libido concerns; hepatotoxicity risk if drinking.

  • Sleep-disordered
    SKIP-FOR-NOW
  • Recovery-focused (post-injury, post-illness)
    OPTIONAL

    if neuropathic pain develops; otherwise gabapentin/pregabalin first-line for that indication.

  • Strength/anabolic-focused
    SKIP-PERMANENT
▸ Subjective experience (deep)

Same SSRI/SNRI emotional blunting and sexual dysfunction. Often nausea early. Pain effect emerges 1-4 weeks. Sedation or activation variable. Withdrawal milder than venlafaxine but real (dizziness, brain zaps).

▸ Tolerance + cycling deep dive
  • Tolerance: Maintained for most.
  • Not cycled.
▸ Stacking deep dive

Avoid stacking with

  • MAOIs.
  • Strong CYP1A2 inhibitors (ciprofloxacin, fluvoxamine) → 2-5x ↑ duloxetine exposure.
  • Hepatotoxic agents (acetaminophen at high cumulative doses, alcohol).
▸ Drug interactions deep dive

CYP1A2 + CYP2D6 substrate. Moderate CYP2D6 inhibitor (less than fluoxetine, more than escitalopram). Watch with TCAs, antipsychotics, codeine.

▸ Pharmacogenomics

CYP2D6 + CYP1A2 phenotypes both relevant. Smokers (CYP1A2 inducers) have lower exposure.

▸ Sourcing deep dive
Path Vendor Cost Reliability Notes
Rx Pharmacy $10-30/mo generic high Generic widely available.
▸ Biomarkers to track (deep)
  • Baseline: PHQ-9, GAD-7, LFTs, BP, sodium.
  • During use: PHQ-9 q4-6 weeks; LFTs if symptoms or alcohol use; BP every visit.
  • Post-discontinuation: Withdrawal symptom diary.
▸ Controversies / open debates Live debate
  • Pain effect size: NNT ~4-7 for clinically meaningful pain reduction in DPN/fibromyalgia — modest but real.
  • Hepatotoxicity signal: FDA labeling cautions against alcohol; case reports of fulminant failure rare but documented.
  • Withdrawal underestimated: Patient communities report longer/worse withdrawal than clinical guidelines acknowledge.
▸ Verdict change log
  • 2026-05-06 — Initial verdict: NOT-RELEVANT.
▸ Open questions / gaps Open

Whether dual mood + pain mechanism produces meaningful synergy vs separate optimization (SSRI + gabapentinoid).

▸ Sources (full, with our context)
Back to compact view